Patents by Inventor Andrew Wollacott

Andrew Wollacott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240132617
    Abstract: The present invention provides, among other things, anti-C3b antibodies with increased specificity and potency and methods of treating C3 glomerulopathy and other complement mediated diseases and disorders using the same.
    Type: Application
    Filed: September 19, 2023
    Publication date: April 25, 2024
    Applicant: Visterra, Inc.
    Inventors: Karthik Viswanathan, Ramki Ramakrishnan, Hedy Adari, Feng Gao, Andrew Wollacott
  • Publication number: 20240076398
    Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
    Type: Application
    Filed: August 18, 2023
    Publication date: March 7, 2024
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
  • Patent number: 11912781
    Abstract: The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.
    Type: Grant
    Filed: January 13, 2022
    Date of Patent: February 27, 2024
    Assignee: Visterra, Inc.
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver, Lauren Olinski
  • Patent number: 11773179
    Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: October 3, 2023
    Assignee: VISTERRA, INC.
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
  • Publication number: 20220356263
    Abstract: The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.
    Type: Application
    Filed: January 13, 2022
    Publication date: November 10, 2022
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
  • Publication number: 20220089764
    Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
    Type: Application
    Filed: January 13, 2021
    Publication date: March 24, 2022
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
  • Patent number: 9243238
    Abstract: Disclosed herein are techniques for computationally designing enzymes. These techniques can be used to design variations of naturally occurring enzymes, as well as new enzymes having no natural counterparts. The techniques are based on first identifying functional reactive sites required to promote the desired reaction. Then, hashing algorithms are used to identify potential protein backbone structures (i.e., scaffolds) capable of supporting the required functional sites. These techniques were used to design 32 different protein sequences that exhibited aldol reaction catalytic function, 31 of which are defined in the Sequence Listing. Details of these 31 different synthetic aldolases are provided, including descriptions of how such synthetic aldolases can be differentiated from naturally occurring aldolases.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: January 26, 2016
    Assignee: University of Washington
    Inventors: David Baker, Alexandre Zanghellini, Lin Jiang, Andrew Wollacott, Daniela Grabs-Röthlisberger, Eric Althoff
  • Patent number: 8340951
    Abstract: Disclosed herein are techniques for computationally designing enzymes. These techniques can be used to design variations of naturally occurring enzymes, as well as new enzymes having no natural counterparts. The techniques are based on first identifying functional reactive sites required to promote the desired reaction. Then, hashing algorithms are used to identify potential protein backbone structures (i.e., scaffolds) capable of supporting the required functional sites. These techniques were used to design 32 different protein sequences that exhibited aldol reaction catalytic function, 31 of which are defined in the Sequence Listing. Details of these 31 different synthetic aldolases are provided, including descriptions of how such synthetic aldolases can be differentiated from naturally occurring aldolases.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: December 25, 2012
    Assignee: University of Washington
    Inventors: David Baker, Alexandre Zanghellini, Lin Jiang, Andrew Wollacott, Daniela Grabs-Röthlisberger, Eric Althoff
  • Publication number: 20120142077
    Abstract: Disclosed herein are techniques for computationally designing enzymes. These techniques can be used to design variations of naturally occurring enzymes, as well as new enzymes having no natural counterparts. The techniques are based on first identifying functional reactive sites required to promote the desired reaction. Then, hashing algorithms are used to identify potential protein backbone structures (i.e., scaffolds) capable of supporting the required functional sites. These techniques were used to design 32 different protein sequences that exhibited aldol reaction catalytic function, 31 of which are defined in the Sequence Listing. Details of these 31 different synthetic aldolases are provided, including descriptions of how such synthetic aldolases can be differentiated from naturally occurring aldolases.
    Type: Application
    Filed: December 1, 2011
    Publication date: June 7, 2012
    Applicant: University of Washington
    Inventors: David Baker, Alexandre Zanghellini, Lin Jiang, Andrew Wollacott, Daniela Grabs-Röthlisberger, Eric Althoff
  • Publication number: 20090191607
    Abstract: Disclosed herein are techniques for computationally designing enzymes. These techniques can be used to design variations of naturally occurring enzymes, as well as new enzymes having no natural counterparts. The techniques are based on first identifying functional reactive sites required to promote the desired reaction. Then, hashing algorithms are used to identify potential protein backbone structures (i.e., scaffolds) capable of supporting the required functional sites. These techniques were used to design 32 different protein sequences that exhibited aldol reaction catalytic function, 31 of which are defined in the Sequence Listing. Details of these 31 different synthetic aldolases are provided, including descriptions of how such synthetic aldolases can be differentiated from naturally occurring aldolases.
    Type: Application
    Filed: December 12, 2008
    Publication date: July 30, 2009
    Applicant: University of Washington
    Inventors: David Baker, Alexandre Zanghellini, Lin Jiang, Andrew Wollacott, Daniela Grabs-Rothlisberger, Eric Althoff